Overview of Phase 1 and 2a Safety and Efficacy Data of Maraviroc (UK-427,857)
description
Transcript of Overview of Phase 1 and 2a Safety and Efficacy Data of Maraviroc (UK-427,857)
Overview of Phase 1 and 2aSafety and Efficacy Data
of Maraviroc (UK-427,857)Mary McHale, Sam Abel,
Deborah Russell, James Gallagher, Elna van der Ryst
Pfizer Global Research and Development, Sandwich Laboratories, Kent, UK
2
Maraviroc (MVC) Maraviroc (UK-427,857, MVC) is a CCR5 antagonist with potent anti-HIV activity in
vitro
An extensive Phase 1/2a program has been carried out
Here we present a summary of the data from the five double-blinded, placebo-controlled, multiple-dose studies with MVC alone, and one drug–drug interaction study with oral contraceptives (expected not to affect exposure to MVC in plasma)
Studies included a total of 259 healthy volunteers and HIV+ positive patients who received MVC at QD and BID doses ranging from 3 mg BID to 1200 mg QD or placebo
Some volunteers received more than one dose of MVC/placebo and are therefore included in more than one dose group in tables and figures.
• Total dosing events for MVC = 220 (154 healthy volunteers, 66 HIV+)• Total dosing events for placebo = 111 (95 healthy volunteers, 16 HIV+)
3
Study Details
Study
(All double-blind, placebo-controlled)
Unit dose range* (mg)
Duration (days)
Dose-escalating multiple-dose study(with wash out periods)1
3–600 10
Oral contraceptive interaction study2 100 7
28–day safety study3 100–300 28
High dose-escalating multiple-dose study 300–1200 7 & 7
Monotherapy study in asymptomatic HIV+ subjects4
25–300 10
Monotherapy study in asymptomatic HIV+ subjects(investigating possible food effect)4
150–300 10
1. Abel S et al. 10th CROI 2003; Paper 547. 2. Russell D et al. 43rd ICAAC 2003; Paper 3080.
*Unit dose refers to actual dose taken at any time point and not total daily dose, several studies included BID doses
3. Abel S et al. 43rd ICAAC 2003; Paper 3066.4. Fätkenheuer G et al. 15th IAC 2004; Abstract TuPeB4489.
4
Demographic Data
Dose
Placebo 150 mg 300 mg 600–1200 mg
N 111 109 50 61
Gender Male 76 90 37 41
Female 35 19 13 20
Age 18–44 104 99 48 61
45–64 7 10 2 0
Race White 104 102 48 60
Black 3 4 1 1
Asian 2 1 0 0
Other 2 2 1 0
5
Most Frequent Adverse Events – Treatment Related
Dose
Adverse Event Placebo 150 mg 300 mg 600–1200 mg
N (%) 111 109 50 61
Headache 17 (15) 19 (17) 12 (24) 18 (30)
Dizziness 7 (6) 8 (7) 5 (10) 27 (44)
Nausea 6 (5) 1 (1) 6 (12) 16 (26)
Asthenia 8 (7) 5 (5) 3 (6) 16 (26)
Flatulence 6 (5) 3 (3) 7 (14) 8 (13)
Rhinitis 1 (1) 2 (2) 2 (4) 14 (23)
Postural hypotension 1 (1) 0 (0) 0 (0) 14 (23)
Abnormal vision 2 (2) 1 (1) 1 (2) 12 (20)
Conjunctivitis 0 (0) 0 (0) 0 (0) 14 (23)
Somnolence 3 (3) 0 (0) 0 (0) 12 (20)
Abdominal pain 3 (3) 1 (1) 2 (4) 7 (11)
6
Postural Hypotension
0
20
40
60
80
100
Placebo <100 mg 100 mg 150 mg 300 mg 600 mg 900 mg 1200 mg
Treatment group
Inci
den
ce o
fp
ost
ura
l hyp
ote
nsi
on
(%
)
Postural hypotension was the dose-limiting AE in phase 1 Occurred at rates in excess of placebo only at doses of 600 mg
3/35
5/17
6/9
2/111 0/36 0/57 0/16 0/50
7
SAEs and Discontinuations
No SAEs reported
11 discontinuations on MVC
• 9 in 154 healthy volunteers in four Phase 1 studies(3 related)
• 2 in 66 HIV+ patients in two Phase 2a studies (not related)
– “no longer willing to participate” (25 mg QD)
– “headache” (100 mg QD fasted)
8 discontinuations on placebo
• 8 in 95 healthy volunteers in four Phase 1 studies (2 related)
• 0 in 16 HIV+ patients in two Phase 2a studies
8
DiscontinuationsDose N Reason for discontinuation Treatment
related*
Severity*
3 mg 1 Transaminases elevated (1) Yes Severe
25 mg 2 Varicella infection (1)
No longer willing to participate (1)
No
-
Moderate
-
100 mg 3 Tooth abscess (1)
Headache (1)
No longer willing to participate (1)
No
No
-
Moderate
Moderate
-
300 mg 2 Protocol violation (1)
Infectious mononucleosis (1)
-
No
-
Moderate
600 mg 3 Postural hypotension (2)
No longer willing to participate (1)
Yes
-
Severe
-
Placebo 8 Postural hypotension(1)
Protocol violation (3)
Sore throat (1)
Laboratory abnormality (1)
Headache (1)
Itchy rash of thorax (1)
Yes
-
No
No
No
Yes
Severe
-
Moderate
Moderate
Mild
Mild
*Investigator assessment
9
Laboratory Abnormalities
Changes in s-creatinine• Elevations in creatinine (<2ULN) in one study
at 1200 mg QD and placebo
• Not seen in other studies where similar exposures to MVC were achieved
Liver-enzyme abnormalities• Sporadic transaminase elevations with no dose relationship
• No associated bilirubin elevations
10
Laboratory Abnormalities
ALT changesin patients with normal ALT at baseline, n
ULN >ULN to 2 ULN
>2ULN to 3ULN
>3ULN to 5ULN
>5ULN Total
Placebo 87 7 1 0 0 95
<100 mg 30 4 0 1 0 35
100 mg 34 6 1 0 0 41
150 mg 11 5 0 0 0 16
300 mg 43 5 0 1 1 50
600 mg 31 2 2 0 0 35
900 mg 14 3 0 0 0 17
1200 mg 7 2 0 0 0 9
ULN = Upper Limit of Normal
11
Max Increase in QTcF From Baseline (msec)
No evidence of dose-related changes in QTcF at dosesof 1200 mg QD
Increase in QTcF from baseline (msec), n (%)
N <30 30–<60 60
Placebo 74 66 (89) 8 (11) 0 (0)
<100 mg 36 32 (89) 3 (8) 1 (3)
100 mg 57 55 (97) 2 (4) 0 (0)
150 mg 16 12 (75) 4 (25) 0 (0)
300 mg 50 47 (94) 3 (6) 0 (0)
600 mg 35 32 (91) 3 (9) 0 (0)
900 mg 17 16 (94) 0 (0) 1 (6)
1200 mg 9 9 (100) 0 (0) 0 (0)
QTcF, Fridericia’s correction
12
MVC Safety Profile Summary
At doses of 300 mg BID, AE profile was similar to placebo
Postural hypotension was the dose-limiting AE – only seen at rates higher than placebo for doses of 600 mg
Clinically relevant elevations in transaminases occurred sporadically, with no dose relationship and no associated elevation in bilirubin
No evidence of clinically relevant prolongation of QTcF
13
MVC Efficacy Results:Mean Reduction in Viral Load over Time
Ch
ang
e fr
om
bas
elin
e (
log
10 H
IV-1
co
pie
s/m
L)
Last day of dosing
Placebo 1015Placebo 100725 mg QD50 mg BID100 mg QD100 mg BID150 mg BID Fast150 mg BID Fed300 mg QD300 mg BID
Maraviroc dose4
1288878888
n
Time (day)5 10 15 20 25 30 35 40Baseline
–2.0
–1.5
–1.0
–0.5
0.0
0.5
Fätkenheuer G et al. 15th IAC 2004; Abstract TuPeB4489
14
MVC Reduces Viral Load in All Patients Receiving Therapeutic Doses
Mean decrease in HIV RNAlog10 copies/mL (range)
HIV RNA decrease>1.0 log10 copies/mL
(no. patients)
Median time to nadir (days)
Dose n Day 11 Nadir Day 11 Nadir
25 mg QD 8 -0.43 (-1.08, 0.02) -0.59 (-1.10, 0.02) 1 1 10
50 mg BID 8 -0.66 (-1.37, 0.40) -0.86 (-1.37, -0.14) 4 5 13
100 mg QD 8 -1.13 (-1.70, -0.43) -1.25 (-1.70, -0.61) 5 6 10
100 mg BID 7 -1.42 (-1.84, -1.04) -1.68 (-2.10, -1.37) 7 7 12
150 mg BID 8 -1.45 (-1.71, -0.90) -1.77 (-2.16, -1.43) 7 8 12
150 mg BID fed 8 -1.34 (-1.79, -0.51) -1.74 (-2.09, -1.13) 7 8 15
300 mg QD 8 -1.35 (-1.62, -0.95) -1.60 (-2.08, -1.14) 7 8 12
300 mg BID 8 -1.60 (-2.42, -0.78) -1.84 (-2.42, -1.49) 7 8 11
15
Emergence of CXCR4-Tropic Virus (1)
61/63 patients (97%) with CCR5-tropic virus at baseline remained CCR5-tropic after 10 days of MVC monotherapy
2 patients showed emergence of CXCR4-using variants during treatment with MVC 100 mg QDfor 10 days
R5 variants remained the predominant virus species post-treatment
Lewis M et al. 44th ICAAC 2004; Poster H-584b
16
Emergence of CXCR4-Tropic Virus (2)
Patient 1
• HIV RNA decline: –0.71 log10 copies/mL
• Transient emergence of dual-/mixed-tropic virus at day 11
• Reverted to CCR5-tropic at day 40.
Patient 2
• HIV RNA decline: –1.26 log10 copies/mL
• Dual-/mixed-tropic virus detected from day 11 onwards
• R5 variants constituted ~80% of the circulating virus after one year’s follow-up.
Phylogenetic analysis suggested that R5/X4 variants which emerged post-treatment in each patient most likely expanded from a pre-treatment R5/X4 virus reservoir, rather thanco-receptor switching of an R5 clone
Lewis M et al. 44th ICAAC 2004; Poster H-584b
17
Conclusions
MVC was safe and well tolerated in doses up toand including 300 mg BID in this population
Doses of 100 mg BID resulted in viral load reductions
of >1 log10 copies/mL
• Dosing with food had no significant effect onviral load reduction
• Dosing of 150 mg BID and 300 mg QD resulted in
similar viral load reductions Currently in Phase 2b/3 development in both naive and
treatment-experienced patients using doses equivalent to 300 mg QD and 300 mg BID
18
Acknowledgements
The maraviroc development team
All the investigators and study-site staff
The patients and volunteers for their participation in these studies